LL-37: complete guide

LL-37 is the 37-amino-acid antimicrobial peptide cut from human cathelicidin. This guide covers its biology, disease links, clinical trials, safety data and FDA status.

Complete guide5 min read

Key takeaway

LL-37 is a 37-amino-acid peptide with a molecular weight of about 4,493 g/mol. A Phase 2b trial in 148 people with venous leg ulcers found no significant healing difference versus placebo. FDA lists cathelicidin LL-37 among compounding substances previously in category 2 that were withdrawn by their nominators.

At a glance

Article typeComplete guide
Regulatory statusNot FDA-approved“LL-37 is not approved by the FDA for any use.” (this article)
ClassImmune & inflammation
Body systemsImmune system
Studies cited5 in this article · 5 across 1 article on LL-37
Related productsBPC-157, TB-500 and thymic peptides

LL-37 is an antimicrobial peptide cut from human cathelicidin, the protein made by the CAMP gene. It is a 37-amino-acid fragment found in white blood cells and in sweat on the skin. This guide covers its biology, its links to skin disease, its clinical trials and its FDA status. Sources were checked on November 17, 2026.

Quick answer: LL-37 is a natural human host defense peptide encoded by the CAMP gene. It kills microbes in lab tests and also steers immune and inflammatory responses. Vitamin D switches on its gene in human cells. It has been tested in small wound and melanoma trials. It is not FDA-approved for any use.

Vitrapep does not sell LL-37; this page is a reference summary of published research and regulatory information.

What is LL-37?

LL-37 comes from a protein called human cathelicidin antimicrobial peptide, or hCAP-18. UniProt maps the full precursor at 170 amino acids. LL-37 is the stretch from position 134 to 170, exactly 37 amino acids long (UniProt P49913). The precursor is stored in neutrophil granules. UniProt also notes that LL-37 is made by sweat glands and “secreted into sweat on skin.”

The gene is CAMP, on chromosome 3. The NCBI gene summary says its protein “plays an important role in innate immunity defense against viruses.” It also lists antibacterial and antifungal activity (NCBI Gene, CAMP). Our guide to peptides versus proteins explains how a peptide can be cut from a larger protein.

PubChem lists LL-37 with the formula C205H340N60O53 and a molecular weight of about 4,493 g/mol. Its listed synonyms include CAP-18 and ropocamptide, its international nonproprietary name (INN) (PubChem CID 16198951).

Table 1

LL-37: key facts

Fact Detail
Structure type Linear peptide, 37 amino acids (LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES)
Class Cathelicidin host defense (antimicrobial) peptide; product of the human CAMP gene
Molecular formula C205H340N60O53
Molecular weight About 4,493 g/mol
Development stage Phase 2b in venous leg ulcers completed (2020); no active registered trial
Sponsor or developer Promore Pharma AB (venous leg ulcer trials, as ropocamptide); academic centers

How does LL-37 work?

LL-37 has two broad roles. The first is direct killing of microbes. UniProt states that it “binds to bacterial lipopolysaccharides (LPS)” and “causes membrane permeabilization by forming transmembrane pores (in vitro).” The same entry calls it “an integral component of the innate immune system.”

The second role is immune signaling. NCBI’s summary says the protein helps direct cell movement, stimulate immune signaling molecules and modulate inflammation. Vitamin D links in here. Human cell studies showed that the CAMP gene “is a direct target of the vitamin D receptor” (Gombart et al., 2005). The authors noted that this induction was not seen in mouse cells.

What is LL-37 being studied for?

LL-37 is not approved by the FDA for any use. Research on it falls into two groups. One group uses the peptide as a treatment candidate. The other studies the body’s own LL-37 as a driver of disease.

  • Venous leg ulcers: a first-in-human trial, then a Phase 2b trial sponsored by Promore Pharma (EudraCT 2018-000536-10, ended July 2020).
  • Melanoma: a Phase 1/2 study at MD Anderson Cancer Center, 4 enrolled (NCT02225366, completed 2020).
  • Diabetic foot ulcers: a Phase 2 study at Universitas Indonesia, 40 listed (NCT04098562, status unknown).
  • Psoriasis and rosacea: lab and patient-sample studies of the body’s own LL-37.

In psoriasis, one study named LL-37 “the key factor that mediates pDC activation.” It found that LL-37 “converts inert self-DNA into a potent trigger of interferon production” (Lande et al., 2007). In rosacea, patients’ facial skin showed “abnormally high levels of cathelicidin.” Mouse experiments supported its role in that inflammation (Yamasaki et al., 2007).

What did the key trials show?

First-in-human venous leg ulcer trial. This randomized, double-blind, placebo-controlled human trial enrolled 34 people. After a run-in period, they were assigned to three LL-37 groups or placebo. Healing rate was higher than placebo in one LL-37 group (p = 0.003), with a trend in a second (p = 0.088). A third LL-37 group did not differ from placebo (Grönberg et al., 2014).

Phase 2b venous leg ulcer trial (HEAL LL-37). This multicenter, double-blind human trial randomized 148 patients to two LL-37 groups or placebo, alongside compression therapy. The authors reported it “did not detect any significant differences in healing” across the full cohort. A post hoc analysis found improvements in patients with large wounds (Mahlapuu et al., 2021). Post hoc subgroup findings need confirmation in a new trial.

What side effects have studies reported?

The first-in-human trial reported no safety concerns for local or whole-body adverse events. The Phase 2b authors described the study drug as “well tolerated and safe” in both LL-37 groups. These were small trials in one condition.

FDA’s compounding safety page raises wider concerns. It says compounded LL-37 “may pose risk for immunogenicity,” meaning unwanted immune reactions. It adds that FDA “lacks sufficient safety-related information regarding cathelicidin LL-37 to know whether the drug would cause harm.” FDA also notes nonclinical findings suggesting harm to male reproduction and possible tumor-promoting effects in some tissues (FDA, 2026).

What is LL-37’s regulatory status, and how is it used in research?

LL-37 is an investigational substance in the United States. FDA’s page, current as of April 22, 2026, lists “Cathelicidin LL-37” among bulk substances “previously in category 2” that “were withdrawn by the nominators.” We did not find LL-37 in any category of FDA’s May 14, 2026 list of substances nominated for 503A compounding (FDA, 2026). Our page on 503A and 503B compounding explains these categories.

Designed compounds such as LTX-315 and brilacidin were modeled on host defense peptides, the family LL-37 belongs to. Our research-use-only explainer covers what that label means.

Frequently asked questions about LL-37

Is LL-37 made in the human body?

Yes. It is cut from the hCAP-18 protein, encoded by the CAMP gene, and is found in neutrophils and sweat.

Is LL-37 FDA-approved?

No. It has been tested only in small clinical trials, and no approval exists.

What is ropocamptide?

Ropocamptide is the INN listed in PubChem for LL-37. Promore Pharma used it for its leg ulcer program.

How is LL-37 linked to vitamin D?

Lab studies in human cells show the vitamin D receptor directly switches on the CAMP gene, which encodes LL-37.

What is LL-37’s compounding status?

FDA lists it as withdrawn by nominators from category 2, its list of substances raising significant safety risks. It is not in FDA’s current 503A categories.

What to know now

  • Structure: 37-amino-acid human cathelicidin peptide; about 4,493 g/mol.
  • Biology: kills microbes in lab tests; modulates immunity; induced by vitamin D in human cells.
  • Disease links: implicated in psoriasis and rosacea in patient and lab studies.
  • Evidence: Phase 2b leg ulcer trial found no significant healing difference overall.
  • Status: not FDA-approved; FDA cites immunogenicity and limited safety data.

What we’re watching

Updates to FDA’s 503A category lists and its compounding safety page. Any new registered trial of LL-37 or ropocamptide. Related guides: LTX-315 and murepavadin.

More for immune system

All 24 compounds for immune system

Sources: UniProt Consortium 2026, UniProtKB P49913: Cathelicidin antimicrobial peptide (Homo sapiens); National Center for Biotechnology Information 2026, Gene ID 820, CAMP cathelicidin antimicrobial peptide (Homo sapiens); National Center for Biotechnology Information 2026, PubChem compound summary for CID 16198951, LL-37; Gombart 2005, The FASEB Journal, 19; Lande 2007, Nature, 449; Yamasaki 2007, Nature Medicine, 13; Grönberg 2014, Wound Repair and Regeneration, 22; Mahlapuu 2021, Wound Repair and Regeneration, 29; Promore Pharma AB 2018; M.D. Anderson Cancer Center 2014, Intratumoral injections of LL37 for melanoma; Fakultas Kedokteran Universitas Indonesia 2019; U.S. Food and Drug Administration 2026; U.S. Food and Drug Administration 2026. All 13 citations

Back to the research library

References

  1. UniProt Consortium. (2026). UniProtKB P49913: Cathelicidin antimicrobial peptide (Homo sapiens). Retrieved November 17, 2026, from https://www.uniprot.org/uniprotkb/P49913/entry
  2. National Center for Biotechnology Information. (2026). Gene ID 820, CAMP cathelicidin antimicrobial peptide (Homo sapiens). Retrieved November 17, 2026, from https://www.ncbi.nlm.nih.gov/gene/820
  3. National Center for Biotechnology Information. (2026). PubChem compound summary for CID 16198951, LL-37. Retrieved November 17, 2026, from https://pubchem.ncbi.nlm.nih.gov/compound/16198951
  4. Gombart, A. F., Borregaard, N., & Koeffler, H. P. (2005). Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. The FASEB Journal, 19(9), 1067-1077. https://doi.org/10.1096/fj.04-3284com
  5. Lande, R., et al. (2007). Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature, 449(7162), 564-569. https://doi.org/10.1038/nature06116
  6. Yamasaki, K., et al. (2007). Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nature Medicine, 13(8), 975-980. https://doi.org/10.1038/nm1616
  7. Grönberg, A., et al. (2014). Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: A randomized, placebo-controlled clinical trial. Wound Repair and Regeneration, 22(5), 613-621. https://doi.org/10.1111/wrr.12211
  8. Mahlapuu, M., et al. (2021). Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: A multicentric prospective randomized placebo-controlled clinical trial. Wound Repair and Regeneration, 29(6), 938-950. https://doi.org/10.1111/wrr.12977
  9. Promore Pharma AB. (2018). A study in patients with hard-to-heal venous leg ulcers to measure efficacy and safety of locally administered LL-37 (EudraCT 2018-000536-10). EU Clinical Trials Register. Retrieved November 17, 2026, from https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-000536-10/results
  10. M.D. Anderson Cancer Center. (2014). Intratumoral injections of LL37 for melanoma (ClinicalTrials.gov ID NCT02225366). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT02225366
  11. Fakultas Kedokteran Universitas Indonesia. (2019). Efficacy of LL-37 cream on bacteria colonization, inflammation response and healing rate of diabetic foot ulcers (ClinicalTrials.gov ID NCT04098562). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT04098562
  12. U.S. Food and Drug Administration. (2026, April 22). Certain bulk drug substances for use in compounding that may present significant safety risks. Retrieved November 17, 2026, from https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  13. U.S. Food and Drug Administration. (2026, May 14). Bulk drug substances nominated for use in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act. Retrieved November 17, 2026, from https://www.fda.gov/media/94155/download